Australia

AACR OVARIAN CANCER CONFERENCE PRESENTATION

HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA.  * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...

2023-10-09 15:18 1870

First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial

SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...

2023-10-03 20:58 2540

FlexRule's Decision-Centric Approach® methodology empowers organizations to make quality decisions, fast

MELBOURNE, Australia, Sept. 28, 2023 /PRNewswire/ -- FlexRule®, a leading Decision Management Suite, is proud to announce that its Decision-Centric Approach® has been officially trademarked. The Decision-Centric Approach® is a methodology that brings people, rules, data, and processes together...

2023-09-28 12:32 2615

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...

2023-09-26 20:51 2245

AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT

ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs, announces two key appointments in the US to support its continued global growth.

2023-09-21 19:30 2139

Körber celebrates partnership milestone with Geek+

HAMBURG, Germany, Sept. 20, 2023 /PRNewswire/ -- Global strategic partnership empowers businesses to overcome efficiency, scalability and sustainability challenges across supply chain Körber  and Geek+ , a global leader ...

2023-09-20 18:34 2871

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer

AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...

2023-09-11 15:00 1652

World Orphan Drug Alliance Welcomes Specialised Therapeutics

* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. * ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA). * Wor...

2023-09-08 04:00 2405

Discover the Legumes From Europe project. Which legumes have the highest amounts of protein and why you should make them part of your diet.

SYDNEY, Sept. 5, 2023 /PRNewswire/ -- Encouraging the consumption of legumes is one of the objectives of theLegumes from Europe campaign led by ANICAV – the National Association of Canned Vegetable Industries – and co-funded by the European Union to promote a healthier and more active lifestyle, ...

2023-09-05 15:00 2123

ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001

*  Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform *  ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data *  ACM is in partnering d...

2023-09-05 14:00 2090

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. * Cohort 2 was recently completed in 3 participants who received therapy...

2023-08-25 20:58 3310

Noodoe Links Californian and Australian Efforts to Combat Global Climate Change

With its newly opened Brisbane offices, Noodoe enables businesses from California to Australia to drive the adoption of sustainable transportation. IRVINE, Calif., Aug. 17, 2023 /PRNewswire/ -- Noodoe today announced the opening of its new offices inBrisbane, Australia as the next step in its wor...

2023-08-18 03:47 2754

THE CONQUEROR TEAMS UP WITH WARNER BROS. DISCOVERY GLOBAL CONSUMER PRODUCTS TO LAUNCH THE ULTIMATE SERIES OF VIRTUAL FITNESS CHALLENGES INSPIRED BY HBO'S GAME OF THRONES

Five Challenges, Five Medals, Following the Extraordinary Journeys of Jon Snow, Tyrion Lannister,Arya Stark, Daenerys Targaryen, and more. TAURANGA, New Zealand, Aug. 16, 2023 /PRNewswire/ -- The Conqueror Virtual Challenges, in collaboration with Warner Bros. Discovery Global Consumer Products,...

2023-08-16 14:00 2372

Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis

SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a glob...

2023-08-15 22:50 2770

HB11 Energy receives grant from US Department of Energy to develop clean, safe and unlimited fusion energy

SYDNEY, Aug. 15, 2023 /PRNewswire/ -- The U.S. Department of Energy (DoE) has awarded a grant toHB11 Energy as part of its 'Innovation Network for Fusion Energy' (INFUSE ) program with the objective, "to accelerate basic research to develop cost-ef...

2023-08-15 21:00 2381

Clarity's theranostic prostate cancer trial advances to highest dose level

Highlights * Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with67Cu SAR-bisPSMA at the dose level of 8GBq. * No dose limiting toxicities (DLTs) ha...

2023-08-10 20:58 2900

AI-based wastewater sampling predicts COVID pressure on hospitals

SYDNEY, Aug. 7, 2023 /PRNewswire/ -- New research shows it is possible to accurately predict hospital admission numbers due to COVID-19 up to four weeks in advance with an Artificial Intelligence (AI) based system using COVID wastewater sampling.

2023-08-07 21:13 2141

Relume Launches World's First AI-Powered Site Builder that exports to Webflow and Figma

SYDNEY, Aug. 7, 2023 /PRNewswire/ -- Sydney-based startup Relume has launched the world's first AI-powered site builder that exports to Webflow and Figma. The new site builder allows users to easily create website wireframes with just a prompt and export them to Figma and Webflow, saving time and...

2023-08-07 15:00 1632

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough c...

2023-08-03 07:00 1741

GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME

* YONDELIS® (trabectedin) now PBS listed for Australian patients * Listing described as "wonderful news" for patients living with rare lipo and leiomyo sarcomas * YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SINGAPORE, July 31...

2023-07-31 15:00 2166
1 ... 12131415161718 ... 47

Week's Top Stories